Intrinsic value of Advaxis - ADXS

Previous Close

$1.48

  Intrinsic Value

$0.30

stock screener

  Rating & Target

str. sell

-80%

Previous close

$1.48

 
Intrinsic value

$0.30

 
Up/down potential

-80%

 
Rating

str. sell

We calculate the intrinsic value of ADXS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  19
  30
  44
  64
  91
  125
  168
  220
  283
  358
  444
  543
  654
  779
  916
  1,065
  1,227
  1,401
  1,586
  1,784
  1,992
  2,211
  2,442
  2,683
  2,935
  3,197
  3,471
  3,755
  4,051
  4,359
Variable operating expenses, $m
  76
  118
  176
  255
  359
  493
  662
  869
  1,118
  1,413
  1,753
  2,144
  2,584
  3,074
  3,615
  4,205
  4,844
  5,530
  6,263
  7,042
  7,865
  8,732
  9,641
  10,593
  11,587
  12,624
  13,704
  14,828
  15,996
  17,210
Fixed operating expenses, $m
  66
  68
  69
  71
  72
  74
  76
  77
  79
  81
  83
  84
  86
  88
  90
  92
  94
  96
  98
  100
  103
  105
  107
  110
  112
  114
  117
  120
  122
  125
Total operating expenses, $m
  142
  186
  245
  326
  431
  567
  738
  946
  1,197
  1,494
  1,836
  2,228
  2,670
  3,162
  3,705
  4,297
  4,938
  5,626
  6,361
  7,142
  7,968
  8,837
  9,748
  10,703
  11,699
  12,738
  13,821
  14,948
  16,118
  17,335
Operating income, $m
  -124
  -156
  -201
  -261
  -341
  -443
  -570
  -727
  -914
  -1,136
  -1,392
  -1,685
  -2,016
  -2,384
  -2,789
  -3,232
  -3,711
  -4,226
  -4,775
  -5,359
  -5,976
  -6,625
  -7,306
  -8,020
  -8,765
  -9,541
  -10,350
  -11,192
  -12,067
  -12,976
EBITDA, $m
  -121
  -153
  -196
  -255
  -332
  -431
  -555
  -707
  -890
  -1,104
  -1,354
  -1,639
  -1,960
  -2,317
  -2,711
  -3,141
  -3,606
  -4,105
  -4,639
  -5,206
  -5,804
  -6,435
  -7,096
  -7,789
  -8,512
  -9,266
  -10,052
  -10,869
  -11,718
  -12,601
Interest expense (income), $m
  0
  0
  1
  3
  6
  9
  14
  20
  27
  37
  48
  61
  76
  93
  113
  135
  159
  185
  214
  245
  277
  312
  349
  387
  428
  470
  515
  561
  609
  659
  711
Earnings before tax, $m
  -124
  -157
  -204
  -267
  -350
  -457
  -590
  -754
  -951
  -1,183
  -1,453
  -1,761
  -2,109
  -2,497
  -2,924
  -3,391
  -3,897
  -4,440
  -5,020
  -5,636
  -6,288
  -6,974
  -7,694
  -8,448
  -9,235
  -10,056
  -10,911
  -11,801
  -12,726
  -13,687
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -124
  -157
  -204
  -267
  -350
  -457
  -590
  -754
  -951
  -1,183
  -1,453
  -1,761
  -2,109
  -2,497
  -2,924
  -3,391
  -3,897
  -4,440
  -5,020
  -5,636
  -6,288
  -6,974
  -7,694
  -8,448
  -9,235
  -10,056
  -10,911
  -11,801
  -12,726
  -13,687

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  70
  107
  161
  233
  329
  452
  607
  797
  1,026
  1,296
  1,609
  1,967
  2,371
  2,821
  3,317
  3,859
  4,445
  5,075
  5,748
  6,462
  7,217
  8,013
  8,847
  9,721
  10,633
  11,585
  12,576
  13,607
  14,679
  15,793
Adjusted assets (=assets-cash), $m
  70
  107
  161
  233
  329
  452
  607
  797
  1,026
  1,296
  1,609
  1,967
  2,371
  2,821
  3,317
  3,859
  4,445
  5,075
  5,748
  6,462
  7,217
  8,013
  8,847
  9,721
  10,633
  11,585
  12,576
  13,607
  14,679
  15,793
Revenue / Adjusted assets
  0.271
  0.280
  0.273
  0.275
  0.277
  0.277
  0.277
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
  0.276
Average production assets, $m
  17
  26
  38
  55
  78
  107
  144
  189
  244
  308
  382
  467
  563
  670
  787
  916
  1,055
  1,205
  1,364
  1,534
  1,713
  1,902
  2,100
  2,307
  2,524
  2,750
  2,985
  3,230
  3,484
  3,749
Working capital, $m
  -8
  -13
  -19
  -27
  -39
  -53
  -71
  -94
  -121
  -152
  -189
  -231
  -279
  -332
  -390
  -454
  -523
  -597
  -676
  -760
  -849
  -942
  -1,040
  -1,143
  -1,250
  -1,362
  -1,479
  -1,600
  -1,726
  -1,857
Total debt, $m
  23
  57
  105
  170
  256
  367
  507
  678
  884
  1,127
  1,409
  1,731
  2,094
  2,499
  2,946
  3,433
  3,961
  4,528
  5,133
  5,776
  6,456
  7,172
  7,923
  8,709
  9,530
  10,387
  11,278
  12,206
  13,171
  14,174
Total liabilities, $m
  63
  97
  145
  210
  296
  407
  546
  718
  923
  1,166
  1,448
  1,771
  2,134
  2,539
  2,986
  3,473
  4,001
  4,567
  5,173
  5,816
  6,496
  7,211
  7,962
  8,749
  9,570
  10,426
  11,318
  12,246
  13,211
  14,214
Total equity, $m
  7
  11
  16
  23
  33
  45
  61
  80
  103
  130
  161
  197
  237
  282
  332
  386
  445
  507
  575
  646
  722
  801
  885
  972
  1,063
  1,158
  1,258
  1,361
  1,468
  1,579
Total liabilities and equity, $m
  70
  108
  161
  233
  329
  452
  607
  798
  1,026
  1,296
  1,609
  1,968
  2,371
  2,821
  3,318
  3,859
  4,446
  5,074
  5,748
  6,462
  7,218
  8,012
  8,847
  9,721
  10,633
  11,584
  12,576
  13,607
  14,679
  15,793
Debt-to-equity ratio
  3.300
  5.310
  6.530
  7.300
  7.800
  8.120
  8.350
  8.500
  8.610
  8.690
  8.750
  8.800
  8.830
  8.860
  8.880
  8.900
  8.910
  8.920
  8.930
  8.940
  8.950
  8.950
  8.960
  8.960
  8.960
  8.970
  8.970
  8.970
  8.970
  8.970
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -124
  -157
  -204
  -267
  -350
  -457
  -590
  -754
  -951
  -1,183
  -1,453
  -1,761
  -2,109
  -2,497
  -2,924
  -3,391
  -3,897
  -4,440
  -5,020
  -5,636
  -6,288
  -6,974
  -7,694
  -8,448
  -9,235
  -10,056
  -10,911
  -11,801
  -12,726
  -13,687
Depreciation, amort., depletion, $m
  2
  3
  4
  6
  8
  11
  15
  19
  25
  31
  38
  47
  56
  67
  79
  92
  106
  120
  136
  153
  171
  190
  210
  231
  252
  275
  298
  323
  348
  375
Funds from operations, $m
  -121
  -154
  -199
  -261
  -342
  -445
  -575
  -735
  -926
  -1,152
  -1,415
  -1,715
  -2,053
  -2,430
  -2,846
  -3,300
  -3,791
  -4,319
  -4,883
  -5,483
  -6,116
  -6,783
  -7,484
  -8,217
  -8,983
  -9,781
  -10,613
  -11,478
  -12,377
  -13,312
Change in working capital, $m
  -3
  -4
  -6
  -9
  -11
  -14
  -18
  -22
  -27
  -32
  -37
  -42
  -47
  -53
  -58
  -64
  -69
  -74
  -79
  -84
  -89
  -93
  -98
  -103
  -107
  -112
  -117
  -121
  -126
  -131
Cash from operations, $m
  -118
  -150
  -193
  -252
  -330
  -431
  -557
  -712
  -899
  -1,120
  -1,378
  -1,672
  -2,005
  -2,377
  -2,787
  -3,236
  -3,722
  -4,245
  -4,804
  -5,399
  -6,027
  -6,690
  -7,386
  -8,114
  -8,875
  -9,669
  -10,496
  -11,357
  -12,251
  -13,181
Maintenance CAPEX, $m
  -1
  -2
  -3
  -4
  -6
  -8
  -11
  -14
  -19
  -24
  -31
  -38
  -47
  -56
  -67
  -79
  -92
  -106
  -120
  -136
  -153
  -171
  -190
  -210
  -231
  -252
  -275
  -298
  -323
  -348
New CAPEX, $m
  -6
  -9
  -13
  -17
  -23
  -29
  -37
  -45
  -54
  -64
  -74
  -85
  -96
  -107
  -118
  -129
  -139
  -150
  -160
  -170
  -179
  -189
  -198
  -207
  -217
  -226
  -235
  -245
  -254
  -264
Cash from investing activities, $m
  -7
  -11
  -16
  -21
  -29
  -37
  -48
  -59
  -73
  -88
  -105
  -123
  -143
  -163
  -185
  -208
  -231
  -256
  -280
  -306
  -332
  -360
  -388
  -417
  -448
  -478
  -510
  -543
  -577
  -612
Free cash flow, $m
  -126
  -160
  -208
  -273
  -359
  -468
  -604
  -772
  -972
  -1,209
  -1,483
  -1,796
  -2,148
  -2,540
  -2,972
  -3,443
  -3,953
  -4,500
  -5,085
  -5,705
  -6,360
  -7,050
  -7,774
  -8,531
  -9,323
  -10,147
  -11,006
  -11,900
  -12,829
  -13,794
Issuance/(repayment) of debt, $m
  23
  34
  48
  65
  86
  111
  139
  171
  206
  243
  282
  322
  364
  405
  446
  487
  528
  567
  605
  643
  680
  716
  751
  786
  821
  856
  892
  928
  965
  1,003
Issuance/(repurchase) of shares, $m
  127
  161
  209
  274
  359
  469
  606
  773
  974
  1,210
  1,484
  1,797
  2,150
  2,542
  2,974
  3,445
  3,955
  4,503
  5,087
  5,708
  6,363
  7,053
  7,777
  8,535
  9,326
  10,151
  11,010
  11,904
  12,833
  13,799
Cash from financing (excl. dividends), $m  
  150
  195
  257
  339
  445
  580
  745
  944
  1,180
  1,453
  1,766
  2,119
  2,514
  2,947
  3,420
  3,932
  4,483
  5,070
  5,692
  6,351
  7,043
  7,769
  8,528
  9,321
  10,147
  11,007
  11,902
  12,832
  13,798
  14,802
Total cash flow (excl. dividends), $m
  24
  35
  49
  66
  87
  112
  140
  172
  207
  244
  283
  324
  365
  407
  448
  490
  530
  569
  608
  646
  683
  719
  754
  790
  825
  860
  896
  932
  969
  1,007
Retained Cash Flow (-), $m
  -127
  -161
  -209
  -274
  -359
  -469
  -606
  -773
  -974
  -1,210
  -1,484
  -1,797
  -2,150
  -2,542
  -2,974
  -3,445
  -3,955
  -4,503
  -5,087
  -5,708
  -6,363
  -7,053
  -7,777
  -8,535
  -9,326
  -10,151
  -11,010
  -11,904
  -12,833
  -13,799
Prev. year cash balance distribution, $m
  50
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  3
  5
  7
  11
  16
  23
  31
  42
  55
  71
  89
  111
  136
  164
  195
  229
  266
  307
  350
  397
  446
  498
  553
  610
  671
  734
  799
  868
  939
  1,013
Cash available for distribution, $m
  -53
  -126
  -160
  -208
  -272
  -357
  -465
  -601
  -767
  -966
  -1,201
  -1,473
  -1,784
  -2,135
  -2,526
  -2,956
  -3,425
  -3,933
  -4,479
  -5,062
  -5,680
  -6,334
  -7,023
  -7,745
  -8,501
  -9,291
  -10,115
  -10,972
  -11,864
  -12,792
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -50
  -115
  -140
  -171
  -211
  -259
  -314
  -375
  -440
  -506
  -570
  -629
  -678
  -717
  -741
  -751
  -745
  -724
  -690
  -643
  -588
  -526
  -460
  -394
  -331
  -271
  -217
  -170
  -130
  -96
Current shareholders' claim on cash, %
  3.4
  0.2
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.

FINANCIAL RATIOS  of  Advaxis (ADXS)

Valuation Ratios
P/E Ratio -0.7
Price to Sales 5.1
Price to Book 1.1
Price to Tangible Book
Price to Cash Flow -0.8
Price to Free Cash Flow -0.7
Growth Rates
Sales Growth Rate 200%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 25%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0.2
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -70.7%
Ret/ On Assets - 3 Yr. Avg. -62.6%
Return On Total Capital -107.5%
Ret/ On T. Cap. - 3 Yr. Avg. -79.7%
Return On Equity -107.5%
Return On Equity - 3 Yr. Avg. -79.7%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -808.3%
EBITDA Margin - 3 Yr. Avg. -902.8%
Operating Margin -825%
Oper. Margin - 3 Yr. Avg. -908.3%
Pre-Tax Margin -816.7%
Pre-Tax Margin - 3 Yr. Avg. -905.6%
Net Profit Margin -775%
Net Profit Margin - 3 Yr. Avg. -875%
Effective Tax Rate 5.1%
Eff/ Tax Rate - 3 Yr. Avg. 3.9%
Payout Ratio 0%

ADXS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ADXS stock intrinsic value calculation we used $12 million for the last fiscal year's total revenue generated by Advaxis. The default revenue input number comes from 2017 income statement of Advaxis. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ADXS stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ADXS is calculated based on our internal credit rating of Advaxis, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Advaxis.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ADXS stock the variable cost ratio is equal to 399%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $65 million in the base year in the intrinsic value calculation for ADXS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Advaxis.

Corporate tax rate of 27% is the nominal tax rate for Advaxis. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ADXS stock is equal to 25%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ADXS are equal to 86%.

Life of production assets of 10 years is the average useful life of capital assets used in Advaxis operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ADXS is equal to -42.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $54 million for Advaxis - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 41 million for Advaxis is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Advaxis at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
PETX Aratana Therap 4.48 0.20  str.sell
AZN AstraZeneca AD 37.17 55.39  str.buy
ADRO Aduro Biotech 6.90 1.13  str.sell
INO Inovio Pharmac 4.32 0.38  str.sell
MRK Merck&Co 62.52 22.92  str.sell
SPPI Spectrum Pharm 23.75 0.58  str.sell
HTBX Heat Biologics 2.24 0.31  str.sell
CLDX Celldex Therap 0.520 0.15  str.sell
INCY Incyte 69.20 51.45  sell

COMPANY NEWS

▶ Biotech Companies with Great Futures   [Jul-16-18 10:45AM  ACCESSWIRE]
▶ Advaxis Provides Update on MAA Filing and ADXS-HOT Program   [Jul-10-18 08:00AM  Business Wire]
▶ Advaxis: Fiscal 2Q Earnings Snapshot   [Jun-07-18 09:25AM  Associated Press]
▶ Advaxis Appoints Molly Henderson as Chief Financial Officer   [Jun-06-18 08:00AM  Business Wire]
▶ Advaxis Announces Executive Leadership Changes   [Apr-23-18 08:00AM  Business Wire]
▶ Advaxis reports 1Q loss   [04:31PM  Associated Press]
▶ Advaxis Inc (NASDAQ:ADXS): Is Breakeven Near?   [Mar-08-18 10:27AM  Simply Wall St.]
▶ Advaxis looks to raise $20 million via share offering   [Feb-22-18 01:05PM  American City Business Journals]
▶ Advaxis Announces Proposed Public Offering of Common Stock   [Feb-21-18 04:05PM  Business Wire]
▶ ETFs with exposure to Advaxis, Inc. : December 27, 2017   [Dec-27-17 10:57AM  Capital Cube]
▶ 3 Stocks Move on Thursday   [Dec-21-17 02:02PM  GuruFocus.com]
▶ Here's Why Advaxis, Inc. Stock Is Getting Pummeled Today   [Sep-12-17 12:34PM  Motley Fool]
▶ Advaxis reports 3Q loss   [Sep-11-17 09:39PM  Associated Press]
▶ What Does Advaxis Incs (ADXS) Share Price Indicate?   [Sep-08-17 07:20PM  Simply Wall St.]
▶ Advaxis CEO Daniel O'Connor resigns   [Jul-06-17 04:48PM  Reuters]
▶ Advaxis Announces Change in Leadership   [04:30PM  Business Wire]
▶ Advaxis Breaks Down From Key Support Levels   [Jun-16-17 09:58AM  Investopedia]
▶ ETFs with exposure to Advaxis, Inc. : June 15, 2017   [Jun-15-17 12:54PM  Capital Cube]
▶ Advaxis to Webcast Investor & Analyst Day 2017   [Jun-09-17 08:00AM  Business Wire]
▶ Advaxis reports 2Q loss   [05:01AM  Associated Press]
▶ Advaxis to Host Investor & Analyst Day on June 12   [May-18-17 08:00AM  Business Wire]
▶ ETFs with exposure to Advaxis, Inc. : May 4, 2017   [May-04-17 03:37PM  Capital Cube]
▶ ETFs with exposure to Advaxis, Inc. : April 21, 2017   [Apr-21-17 02:42PM  Capital Cube]
▶ Advaxis Appoints Anthony Lombardo as Chief Business Officer   [Apr-19-17 08:00AM  GlobeNewswire]
▶ ETFs with exposure to Advaxis, Inc. : March 27, 2017   [Mar-27-17 03:47PM  Capital Cube]
▶ EMA Certification Paves Way for Advaxis Drug   [Mar-23-17 01:36PM  Investopedia]
▶ EMA Certification Paves Way for Advaxis Drug   [01:36PM  at Investopedia]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.